

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 007157/270549

First Inventor Snyder

Title CURCUMIN ANALOGS WITH ANTI-TUMOR AND
ANTI-ANGIOGENIC PROPERTIES

Express Mail Label No. EV184330236US

223586 U.S.PTO
10/690462

ADDRESS TO: **MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: James P. SNYDER; Matthew C. DAVIS; Brian ADAMS; Mamoru SHOJI;
Dennis C. LIOTTA; Eva M. FERSTL; Ustun B. SUNAY

Assignee of this invention is Emory University.

1. The Filing Fee has been calculated as shown below:
2. Applicant claims Small Entity Status. See 37 CFR 1.27.

No. Filed	No. Extra	Small Entity Rate	Fee 1	Large Entity Rate	Fee 0
BASIC FEE			\$385		\$0
TOTAL CLAIMS:	8 - 20 = 0		X 9 = \$0	x 18 = \$0	
INDEP CLAIMS:	3 - 3 = 0		X 43 = \$0	x 86 = \$0	
[<input type="checkbox"/>] MULTIPLE DEPENDENT CLAIMS PRESENTED			+145 = \$0	+290 = \$0	
*If the difference in Column 1 is less than zero, enter "0" in Column 2.		TOTAL	\$385	TOTAL	\$0

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Acct. No. _____.

a. Fees required under 37 CFR 1.16 (National filing fees).
b. Fees required under 37 CFR 1.17 (National application processing fees) including any extension of time fees under 37 CFR § 1.136(a) that are required for consideration of papers filed during prosecution.

1. A check in the amount of \$0.00 for the filing fee is enclosed.

2. The above filing fee will be paid along with Applicants' Response to Notice to File Missing Parts.

3. Specification; Total Pages 59

4. 5 Sheets of Drawings (35 USC 113)

5. Declaration and Power of Attorney (0 pages)

- a. Newly executed (original or copy)
- b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

- a. Computer Readable Copy (CRF)
- b. Request for Transfer of Computer Readable Form of Sequence Listing under 37 CFR § 1.821(e) and MPEP 2422.05 (must be compliant with new rules)
- c. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. Paper (pages)
- d. Statements verifying identity of above copies.

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & documents including a check for the \$40.00 fee)

10. 37 CFR 3.73(b) Statement (*when there is an assignee*); Power of Attorney

11. English Translation Document (*if applicable*)

12. Information Disclosure Statement (IDS) and Form PTO-1449 (citations w/o copies)

13. Preliminary Amendment (pages)

14. Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)

15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
 Foreign Priority is claimed as Application No. , filed

16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i).
 Applicant **must** attach form PTO/SB35 or its equivalent.

17. Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.

18. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:**
 Continuation Divisional Continuation in Part (CIP)


of prior Application No: 09/729,662; Filed: December 4, 2000

Prior Application Information: Examiner: V. Balasubramanian Group/Art Unit: 1624

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. **CORRESPONDENCE ADDRESS**

CUSTOMER NUMBER 00826

Signature: 

Attorney of Record: Ryan W. Cagle
 Attorney Registration No. 47,468

Alston & Bird LLP


Bank of America Plaza
 101 South Tryon Street, Suite 4000
 Charlotte, NC 28280-4000

Tel Raleigh Office (919) 862-2200
 Fax Raleigh Office (919) 862-2260

"Express Mail" mailing label number: EV184330236US

Date of Deposit: October 21, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


 Rebecca Kerney